Furthermore, a phase I/II trial with SBRT plus anti-OX40 in patients suffering from metastatic breast cancer (NCT01862900) and a phase Ib trial with cyclophosphamide, RT, and anti-OX40 in patients with progressive metastatic prostate cancer (NCT01303705) are currently ongoing with results not yet published. This evidence concerns the gene TNFRSF4 and metastatic prostate carcinoma.